无创通气治疗肾移植术后重症肺炎所致ARDS的疗效
该回顾性研究纳入2014年1月1日至2016年6月1日四川省人民医院17例肾移植术后重症肺炎所致ARDS并接受NIV治疗的患者,按NIV结局分为成功组9例与失败组8例。失败组APACHE II评分、PCT、BNP、SCr、他克莫司日剂量及NIV支持条件均显著高于成功组,治疗后PaO2/FiO2显著低于成功组。ROC曲线显示APACHE II评分、PCT、BNP、他克莫司日剂量及NIV后PaO2/FiO2变化对NIV疗效有较高预测价值,SCr预测不敏感。作者认为NIV对该人群有一定价值,他克莫司日剂量越小、APACHE II评分及PCT、BNP越低、NIV后PaO2/FiO2改善越明显,疗效越好。
要点
- NIV失败组APACHE II评分16.7±5.7 vs 成功组10.3±2.1,PCT 32.8(1.2, 187.7)μg/L vs 0.3(0.1, 2.9)μg/L,均P<0.05。
- NIV失败组BNP 832.4(263.7, 1180.2)ng/L vs 成功组157.0(33.9, 218.5)ng/L,他克莫司日剂量3.6(3.1, 4.0)mg vs 2.6(2.0, 3.5)mg,均P<0.05。
- NIV失败组IPAP 14.8±4.1 cmH2O vs 成功组9.0±1.1 cmH2O,EPAP 7.6±1.8 cmH2O vs 4.7±0.8 cmH2O,FiO2 0.75±0.25 vs 0.43±0.06,均P<0.05。
- 治疗后PaO2/FiO2失败组107.4±65.2 mmHg vs 成功组268.7±98.8 mmHg,P<0.05;ROC示BNP的AUC 0.903最高,APACHE II评分AUC 0.813。
- APACHE II评分界值16.0、PCT 4.1 μg/L、BNP 180.5 ng/L、他克莫司日剂量2.5 mg、PaO2/FiO2升高49.5 mmHg时敏感度分别为87.5%、75.2%、87.5%、87.5%、75.0%,特异度分别为77.8%、66.7%、88.9%、74.4%、88.9%;SCr预测不敏感。
适用人群与场景
- 肾移植术后确诊为重症肺炎所致ARDS并接受NIV治疗的患者,来自四川省人民医院2014年1月1日至2016年6月1日的回顾性资料。
研究设计与关键结果
- 回顾性分析17例肾移植术后重症肺炎所致ARDS接受NIV治疗的患者,按NIV结果分为成功组9例与失败组8例。
- 两组性别、年龄、基础疾病无显著差异;失败组APACHE II评分、PCT、BNP、SCr、他克莫司日剂量及NIV支持条件(IPAP、EPAP、FiO2)显著高于成功组(均P<0.05)。
- 治疗后PaO2/FiO2失败组107.4±65.2 mmHg vs 成功组268.7±98.8 mmHg,P<0.05。
- Alb、WBC、吗替麦考酚酯日剂量、糖皮质激素使用、NIV时长、pH值、PaCO2、排痰障碍或气胸发生率两组无显著差异。
- ROC曲线:APACHE II评分、PCT、BNP、他克莫司日剂量、NIV后PaO2/FiO2变化的AUC分别为0.813、0.778、0.903、0.778、0.764;SCr对NIV疗效预测不敏感。
证据类型、等级与局限
- 证据类型:回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为NIV治疗肾移植术后重症肺炎所致ARDS有一定价值;他克莫司日剂量越小、APACHE II评分及PCT、BNP越低、NIV后PaO2/FiO2改善越明显,疗效越好。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To observe the clinical efficacy of noninvasive ventilation (NIV) on the treatment of acute respiratory distress syndrome (ARDS) caused by severe pneumonia after kidney transplantation.
METHODS: The clinical data of 17 patients who were diagnosed as ARDS caused by severe pneumonia after kidney transplantation and treated with NIV in Sichuan Provincial People's Hospital from January 1st, 2014 to June 1st, 2016 were collected and retrospectively analyzed. According to the result of NIV treatment, the patients were divided into NIV success group (n = 9) and NIV failure group (n = 8). The differences in gender, age, underlying diseases, acute physiology and chronic health evaluation II (APACHE II) score, laboratory parameters on the day when ARDS was diagnosed, daily immunosuppressive dosage, NIV support condition and duration, arterial blood gas analysis and adverse reactions between the two groups were compared. Receiver operating characteristic curve (ROC) was plotted, and the predictive value of each parameters for NIV results was evaluated.
RESULTS: The two groups were similar in gender, age, and underlying diseases. The APACHE II score, serum levels of procalcitonin (PCT) and brain natriuretic peptide (BNP), serum creatinine (SCr), daily tacrolimus dose, and NIV support condition in NIV failure group were significantly higher than those in NIV success group [APACHE II score: 16.7±5.7 vs. 10.3±2.1, PCT (μg/L): 32.8 (1.2, 187.7) vs. 0.3 (0.1, 2.9), BNP (ng/L): 832.4 (263.7, 1 180.2) vs. 157.0 (33.9, 218.5), SCr (μmol/L): 284.8 (90.5, 474.2) vs. 186.6 (76.7, 206.3), daily tacrolimus dose (mg): 3.6 (3.1, 4.0) vs. 2.6 (2.0, 3.5), inspiratory positive airway pressure (IPAP, cmH2O, 1 cmH2O = 0.098 kPa): 14.8±4.1 vs. 9.0±1.1, expiratory positive airway pressure (EPAP, cmH2O): 7.6±1.8 vs. 4.7±0.8, fraction of inspired oxygen (FiO2): 0.75±0.25 vs. 0.43±0.06, all P < 0.05], and the oxygenation index (PaO2/FiO2) after treatment was significantly lower than that of NIV success group [mmHg (1 mmHg = 0.133 kPa): 107.4±65.2 vs. 268.7±98.8, P < 0.05]. There was no significant difference in albumin (Alb), white blood cell count (WBC), daily mycophenolate mofetil dose, use of glucocorticold, NIV duration, pH value, arterial partial pressure of carbon dioxide (PaCO2), or the incidence of sputum drainage disorder or pneumothorax between the two groups. ROC curve analysis showed that the predictive value of APACHEII score, serum PCT and BNP levels, tacrolimus daily dosage and PaO2/FiO2 changes after NIV treatment for the efficacy of NIV was high, the area under the ROC curve (AUC) was 0.813, 0.778, 0.903, 0.778, 0.764, respectively; when the cut-off value of APACHE II score was 16.0, PCT was 4.1 μg/L, BNP was 180.5 ng/L, tacrolimus daily dosage was 2.5 mg, PaO2/FiO2 increased 49.5 mmHg, the sensitivity was 87.5%, 75.2%, 87.5%, 87.5% and 75.0%, respectively, and the specificity was 77.8%, 66.7%, 88.9%, 74.4%, 88.9%, respectively. However, SCr was not sensitive to the NIV effect prediction.
CONCLUSIONS: NIV in the treatment of ARDS caused by severe pneumonia after kidney transplantation has a certain value. The fewer tacrolimus daily dosage, the lower APACHE II score and levels of PCT and BNP, the more effective promotion of PaO2/FiO2 after NIV treatment, and the better curative effect is suggested.
参考来源
- Liu X, Xie Z, Teng H, et al. [Efficacy of noninvasive ventilation on treatment of ARDS caused by severe pneumonia after kidney transplantation]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017. PMID: 29151414. doi:10.3760/cma.j.issn.2095-4352.2017.11.007
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。